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Abstract
Hemorrhage is responsible for 30 to 40% of all trauma-related mortality. Among adult trauma patients, 94% of
hemorrhage-related deaths occur within 24 h and approximately 60% of these deaths within 3 h of hospital
admission. Therefore, appropriate initial fluid resuscitation for bleeding is crucial to avoid preventable trauma-
related death. In particular, the resuscitation strategy must be designed to complement prompt correction of
anemia, coagulopathies, and thrombocytopenia. Conventional damage control resuscitation (DCR) of patients with
severe trauma and massive hemorrhage is usually begun with rapid infusion of 1000 to 2000 mL of crystalloid fluids
with subsequent transfusion of type O or uncross-matched red blood cells (RBCs) without plasma such as fresh
frozen plasma (FFP) or platelets (PLTs). However, this DCR technique often leads to several adverse events such as
abdominal compartment syndrome, acute respiratory distress syndrome, multiple organ failure, and dilutional
coagulopathy. Simultaneous transfusion of FFP and PLTs along with the first units of RBCs while minimizing
crystalloid infusion was recently recommended as a renewed DCR strategy. This aggressive RBC transfusion with
FFP and PLTs is not only essential for the correction of coagulopathies and thrombocytopenia but also has the
potential to ensure a good outcome in trauma patients. Additionally, it is important to maintain the resuscitation
ratios of FFP/RBC and PLT/RBC. Most recently, DCR has been advocated for rapid hemorrhage control through early
administration of a mixture of FFP, PLTs, and RBCs in a balanced ratio of 1:1:1.
Keywords: Transfusion, Plasma, Fresh frozen plasma, FFP, Platelet, Trauma, Damage control resuscitation, Acute
traumatic coagulopathy, Acute coagulopathy of trauma shock, Trauma-induced coagulopathy
Background
Trauma is a major health care issue that results in the
annual death of 5–8 million people worldwide [1]. It is
the sixth most common cause of death in Japan and the
third most common in the USA. Hemorrhage is respon-
sible for 30–40% of total trauma-related mortality [2].
Among adult trauma patients, 94% of hemorrhagic
deaths occur within 24 h and ~60% of these deaths
within 3 h of hospital admission [3].
Bleeding in trauma is due to vascular damage, but in
25–30% of patients, it is also due to trauma-induced coag-
ulopathy [1, 4–6]. It was long presumed that the main
causative factor in traumatic coagulopathy was iatrogenic
hemodilution. However, traumatic coagulopathy was
recently shown to already develop at the trauma scene,
before any medical intervention [7]. This finding is of
particular relevance given that traumatic coagulopathy
results in considerably increased mortality [4, 5, 8, 9].
In the early phase of injury, rapid surgical or angio-
graphic hemostasis is the first priority in avoiding
trauma-related death. Preventable trauma death (PTD)
may be attributable to the absence of appropriate initial
resuscitation for bleeding. Therefore, any effective resus-
citation strategy must be designed to complement the
appropriate and prompt correction of anemia, coagulop-
athy, and abnormalities in fibrinolysis.
The damage control resuscitation (DCR) strategy,
which is focused on halting and/or preventing the lethal
triad of coagulopathy, acidosis, and hypothermia, has
challenged traditional thinking on early resuscitation
strategies [10]. In DCR, transfusion is carried out during
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the early stage of patient management. It involves the
use of increased amounts of plasma and platelets (PLTs)
along with the first units of red blood cells (RBCs), while
simultaneously minimizing crystalloid administration in
patients who are predicted to require massive transfu-
sion (defined as >10 units of RBCs in 24 h) [10–13].
Coagulopathy during the pre-hospital stage
Our understanding of major hemorrhage in trauma has
dramatically changed over the past decade, mainly due
to the recognition that patients who are bleeding when
they present to the hospital already have an established
coagulopathy, before the dilutional effects of fluid resus-
citation. This has led to the use of a new terminology:
acute traumatic coagulopathy (ATC) or acute coagulopa-
thy of trauma shock, or trauma-induced coagulopathy
(TIC). ATC/TIC quickly follows severe and profound
injury and is present in one quarter to one third of these
patients at the time of hospital admission [14, 15].
The importance of ATC/TIC is that its presence is a
prognostic indicator, based on its association with a poor
clinical outcome. In traumatic hemorrhage patients, a
prolonged prothrombin time (PT) and/or activated
partial thromboplastin time (aPTT) at hospital admis-
sion, before resuscitation, is associated with a three- to
fourfold higher mortality and independently associated
with increased transfusion requirements, organ dysfunc-
tion, and critical care length of stay [16, 17].
ATC/TIC is a multifactorial, global failure of the coagu-
lation system to sustain adequate hemostasis after major
trauma. Its pathophysiology is thought to be due to the
massive stimulation of thrombin generation, PLT con-
sumption, and fibrinolysis by damaged tissues [18, 19].
Tissue damage exposes tissue factor, which drives throm-
bin generation and activation of the coagulation cascade.
Thrombin activates PLTs, leukocytes, tissue plasminogen
activator (t-PA), and the endothelium. Other factors that
activate t-PA include hypoxia and vasopressors [17].
The development of coagulopathy in the
emergency department
In the 1970s and 1980s, resuscitation of the most severely
injured and massively hemorrhaging patients usually
began with the rapid administration of 1000–2000 mL of
crystalloid fluids, followed by type O or uncross-matched
RBCs. However, the administration of significant amounts
of crystalloid leads to abdominal compartment syndrome,
acute respiratory distress syndrome (ARDS), and multiple
organ failure [20]. Ley et al. [21] determined that the
replacement of ≥1.5 L of intravenous crystalloids in the
emergency department is an independent risk factor for
mortality. High volumes of crystalloids (>3 L) are associ-
ated with a high mortality rate, particularly in elderly
trauma patients. Additionally, in this setting, low blood
volume, insensible losses and/or consumption, and resus-
citation with plasma-poor RBCs rapidly lead to plasma
coagulation factor concentrations of <40%, even before 10
units of RBCs have been transfused. However, the early
initiation of plasma therapy is often delayed by its lack of
immediate availability in the trauma center. Additionally,
while PLT concentrations usually fall to 50–100 × 109/L
(=50,000–100,000/μL) after 10–20 units of RBCs have
been administered, in individual patients, they are quite
variable and larger decreases are possible [22]. Conse-
quently, delays in the early initiation of PLT therapy are
typically greater than those in plasma administration.
Situation of dilutional coagulopathy and
thrombocytopenia according to differences in
blood components
Kornblith et al. [23] obtained 23 units of fresh frozen
plasma (FFP), PLT concentrate, and RBCs from a
regional blood collection center and mixed them to
create 23 units of 1:1:1 and 1:1:2 reconstituted whole
blood (RWB) (Fig. 1). They then measured the inter-
national normalized ratio (INR)/partial thromboplastin
time (PTT) and performed a complete blood cell count,
functional studies, and an extensive panel of procoagu-
lant and anticoagulant factor assays using these prod-
ucts. The hemoglobin (Hgb) and hematocrit (Hct) were
significantly lower in patients administered 1:1:1 RWB
than 1:1:2 RWB, but the former had a higher PLT count.
Moreover, the PLT counts were typically only 70% of the
transfused circulating PLTs. Notably, 1:1:1 RWB patients
had a significantly lower INR and PTT than did 1:1:2
RWB patients and a significantly higher fibrinogen level
(Table 1). Previous studies [24, 25] showed that an INR
or PTT ratio >1.5 and low PLT counts were strongly
associated with uncontrolled microvascular bleeding and
hemorrhage-related mortality [26]. Therefore, caution
is warranted regarding the use of therapy with blood
components, as an inappropriate unit ratio will lead to
dilutional coagulopathy and thrombocytopenia.
FFP transfusion
Colloid or crystalloid in DCR?
The overuse of crystalloids before the administration of any
blood product as a primary initial resuscitative solution in
patients with hemorrhagic shock leads to dilutional coagu-
lopathy, pulmonary edema (ARDS), and severe interstitial
edema (abdominal compartment syndrome). Furthermore,
because crystalloid- or colloid-based resuscitation causes
acidosis, and a steady decline in oxygen delivery, the under-
lying coagulation and metabolic disorders that evolve after
injury and blood loss are further aggravated [27].
However, for the last four decades, most trauma resus-
citations have consisted of an initial 2000 mL of crystal-
loid given according to the early protocols of the
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American College of Surgeons’ Advanced Trauma Life
Support course. During the same period, there was
little argument about PLT administration. However,
this resulted in unintentional hemodilution, which led
to a vicious circle of coagulopathy, acidosis, and
hypothermia, the “lethal triad of trauma” [28].
Importance of FFP transfusion and the FFP/RBC ratio
Cinat et al. [29] reported that early aggressive transfusion
with FFP is essential to the correction of coagulopathy
and results in a good outcome in trauma patients. Accord-
ing to Hirshberg et al. [30], prolongation of the PT to >1.8
times normal is the sentinel event of dilutional coagulopa-
thy and the key to preventing coagulopathy is plasma infu-
sion before the PT becomes subhemostatic. Based on a
computer simulation, those authors concluded that the
optimal replacement FFP/RBC and PLT/RBC ratios were
2:3 for plasma and 8:10 for PLTs to minimize dilutional
coagulopathy. In the early 2000s, the two-part DCR
concept was proposed for severely injured patients. The
strategy is initiated within minutes of the arrival of
these patients in the emergency department, with re-
suscitation initially limited to maintaining blood pressure
at ~90 mmHg; this so-called permissive hypotension
prevents renewed bleeding from recently clotted vessels.
In the second step, intravascular volume restoration is
accomplished using plasma as the primary resuscitation
fluid in at least a 1:1 or 1:2 ratio of FFP/RBC [13].
Many studies have evaluated the effects of the FFP/RBC
on mortality in massive transfusion after trauma (Table 2).
Most of them demonstrated a survival advantage of an
Fig. 1 Conventional blood products and effects of administering them in ratios. a Composition of standard units of the following blood
components: RBCs, FFP, and WBD PLTs. All PLT units in the Pragmatic Randomized Optimal Plasma and Platelet Ratios (PROPPR) study and 85%
of PLTs used in the USA are in the form of apheresis units equal to six WBD units. The 55 billion PLTs in one WBD PLT unit occupy <0.5 mL. b
Composition of the constituents in 1:1:1 and 1:1:2 mixtures of FFP, WBD PLTs, and RBC units. The top row is calculated directly from the contents,
reflecting the extent to which anticoagulant and RBC additive solution dilute plasma and PLTs and RBCs are diluted by mixing with the other
components. In the bottom row, the international normalized ratio and partial thromboplastin time values come from the experimental data of
Kornblith et al. [23], whereas the circulating PLT counts given are 70% of the infused PLT counts to reflect the poor recovery of stored PLTs.
Reproduced with permission [12]. RBCs red blood cells, FFP fresh frozen plasma, WBD whole blood-derived, PLTs platelets
Table 1 Clotting profiles by RWB variants (1:1:1 vs. 2:1:1)
1:1:1 2:1:1
n = 23 SD n = 23 SD p
INR 1.31 0.18 1.55 0.31 0.0029
PT, s 15.98 1.71 18.20 2.75 0.0024
PTT, s 41.76 4.68 49.92 8.12 0.0008
Hgb, g/dL 9.05 1.07 12.15 1.22 0.0000
Hct, % 28.93 3.46 39.19 3.90 0.0000
PLTs, ×109/L 129.62 22.23 95.48 21.85 0.0000
Data are given as mean and SD. Significance assessed by Student’s t test for
normally distributed data and Wilcoxon rank-sum test for nonnormally
distributed data
RWB reconstituted whole blood, INR international normalized ratio, PT
prothrombin time, PTT partial thromboplastin time, Hgb hemoglobin, Hct
hematocrit, PLTs platelets
p < 0.05, significant
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increased plasma ratio, with the majority suggesting an
optimal FFP/RBC ratio of ≥1:2.
However, this approach has not been tested in pro-
spective randomized controlled trials.
The Prospective, Observational, Multicenter, Major
Trauma Transfusion (PROMMTT) Study Group, a
highly publicized prospective cohort study, documented
the timing of transfusions during active resuscitation
and the respective patient outcomes [3]. In the first 6 h
after admission, patients with an FFP/RBC ratio of <1:2
were three to four times more likely to die than patients
with ratios of ≥1:1. Higher plasma ratios early in resusci-
tation were associated with a decreased mortality in
patients who received transfusions of at least three total
units of RBCs, FFP, or PLTs during the first 24 h after
admission. In a multivariable time-dependent Cox model,
an increased FFP/RBC ratio was independently associated
with a decrease in 6-h post-admission mortality (adjusted
hazard ratio = 0.31; 95% confidence interval, 0.16–0.58),
when hemorrhagic death predominates. Hagiwara et al.
[31] also reported that in severe blunt trauma patients
(injury severity score ≥16), the transfusion of an FFP/RBC
ratio of ≥1 within the first 6 h was related to outcome.
These results provide strong support for the early and
high-dose administration of FFP in DRC blood trans-
fusion therapy.
Platelet transfusion
In severe trauma patients, massive transfusions of RBCs
and FFP and other intravenous fluids give rise to dilu-
tional thrombocytopenia. However, many studies have
shown that in the early stages of trauma hemorrhage
thrombocytes are maintained at levels not expected to
contribute to a clinically significant coagulopathy [32].
Thus, while PLT transfusion may not be essential for the
correction of ATC/TIC, together with the combined
effects of shock, hypothermia, etc., ATC theoretically
produces aberrant PLT function by disrupting activation
and adhesion pathways.
Starting time of platelet transfusion
In Japan, there are no clear criteria regarding the starting
time of PLT transfusion for trauma patients, whereas in
Europe, there is a guideline for the management of
bleeding and coagulopathy following major trauma. Ac-
cording to the European guideline, in grade 1C patients,
PLTs should be administered to maintain a concentra-
tion of >50 × 109/L. In grade 2C patients, the mainten-
ance of a PLT count of >100 × 109/L is recommended for
patients with ongoing bleeding and/or traumatic brain
injury, with an initial dose of four to eight single PLTs
units or one apheresis pack [1]. The guideline for the
administration of PLTs, however, is based mainly on
observational studies and opinions.
Ciavarella et al. [33] reported that the most sensitive
laboratory predictors of diffuse non-mechanical micro-
vascular bleeding (MVB) were a PLT count <50 × 109/L
(=50,000/μL) or a fibrinogen level of <0.5 g/L. Accord-
ingly, a PLT count of <50 × 109/L (=50,000/μL) may
serve as one of the criteria for the starting time of PLT
administration in severe trauma patients, even in the
absence of MVB. This starting time is consistent with
the study by Johansson et al. [34] of patients with a rup-
tured abdominal aortic aneurysm, in whom 30-day survival
was related to the PLT count determined upon arrival at
the intensive care unit (ICU); this PLT count in the ana-
lyzed patients was well above the recommended 50 × 109/L.
However, some patients are able to maintain high PLT
counts despite ongoing blood loss by recruiting PLTs from
the spleen and possibly mobilizing new ones from bone
marrow. Thus, when >220% of blood volume has been
replaced, PLT counts will usually have fallen to around
50 × 109/L and frank coagulopathy will ensue [35].
Based on their small prospective study of 27 patients re-
quiring massive transfusion, Counts et al. [36] concluded
Table 2 Effects of FFP/RBC ratio on mortality outcome
Authors Year Patients FFP/RBC ratio Results
Borgman 2007 246 <1:4 vs. 1:4—1:2 vs. >1:2 Improved in-hospital survival in highest ratio group (OR 8.6, CI 2.1–35.2)
Maegele 2008 713 <0.9 vs. 0.9—1.1 vs. >1.1 Decreased 30-day mortality in highest ratio group (24 vs. 46%, p < 0.001)
Duchesne 2008 135 <1:2 vs. >1:2 Increased mortality in low-ratio group (RR 18.9; CI 6.3–56.4)
Holcomb 2008 466 <1:2 vs. ≥1:2 Improved 30-day survival in high plasma transfusion group (73 vs. 43%, p < 0.001)
Zink 2009 466 <1:4 vs. 1:4—1:1 vs. ≥1:1 Decreased in-hospital mortality in high plasma transfusion groups (ARR of 29%)
Sperry 2008 415 <1:1.5 vs. ≥1:1.5 High plasma ratio is independently associated with lower mortality
(HR 0.48, CI 0.3–0.8)
Gunter 2008 259 <2:3 vs. ≥2:3 Decreased 30-day morality in high plasma transfusion groups
Kashuk 2008 133 1:1 vs. 1:2 vs. 1:3 vs. 1:4 vs. ≥1:5 The lowest predicted mortality probability correlates with a plasma/red cell ratio
of 1:2 and 1:3.
Teixeira 2009 383 ≤1:8 vs. 1:8—1:3 vs. 1:3—1:2 vs. >1:2 Linear correlation between survival and plasma transfusion ratio. No survival
advantage after plasma transfusion ratio reaches 1:3
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that the most useful parameter for estimating the need for
PLT transfusions was the PLT count, with a count as high
as 100 × 109/L potentially required to control bleeding
from surgical wounds and serving as the threshold level
for starting PLT transfusion.
A PLT count of <100 × 109/L is a possible risk factor for
mortality, and a PLT count of <50 × 109/L leads to lethal
coagulopathy. Therefore, PLT administration should be
started when the PLT count is <100 × 109/L, and it should
be maintained at >50 × 109/L in patients with severe
trauma and/or ongoing bleeding. However, in one study,
only 3% of trauma patients had a PLT count of <100 ×
109/L at ICU admission [37], so a delay in the start of
platelet administration should be avoided.
Ratio of the platelet transfusion
In massive transfusions (>10 units of RBCs within 24 h
of admission), the resuscitation ratios of both FFP/RBC
and PLT/RBC are undoubtedly important in reducing
hemorrhagic mortality. However, neither civilian nor
military practice has yielded a consensus on optimal
PLT transfusions.
Inaba et al. [38] evaluated the impact of PLT transfu-
sion in trauma patients receiving massive transfusion.
With a decreasing PLT/RBC ratio, mortality at 24 h
increased in a stepwise fashion. Compared with the
group with the highest ratio (>1:6), the adjusted relative
risk of death was 1.67 (adjusted p = 0.054) in the high-
ratio group (≥1:12 and <1:6), 2.28 (adjusted p = 0.013) in
the medium-ratio group (≥1:18 and <1:12), and 5.51
(adjusted p < 0.001) in the low-ratio group (<1:18). A
similar stepwise increase in mortality with a decreasing
PLT/RBC ratio was observed at 12 h after admission.
After stepwise logistic regression, a high PLT/RBC ratio
was independently associated with improved survival at
24 h (adjusted p < 0.001) (Fig. 2). Holcomb et al. [10]
also determined the effect of the blood component ratio
in massive transfusion. Patients with a high PLT/RBC
ratio (≥1:2) had a significantly higher 30-day survival
than those with a low PLT/RBC ratio (<1:2) (high 59.9%
vs. low 40.1%, p < 0.01) as did those with a high (≥1:2)
vs. low (<1:2) FFP/RBC ratio (high 59.6% vs. low 40.4%,
p < 0.01). The authors concluded that not only a PLT/
RBC ratio of ≥1:2 but also an FFP/RBC ratio of ≥1:2 was
shown to be optimal and that both ratios were inde-
pendent predictors of death at 6 and 24 h and at 30 days.
These two treatment groups were then expanded to four
in a 2 × 2 factorial layout (group 1: high FFP and PLT
ratio; group 2: high FFP and low PLT ratio; group 3: low
FFP and high PLT ratio; and group 4; low FFP and low
PLT ratio). Kaplan–Meier analysis showed a significant
separation of the groups within 6 and 24 h (p < 0.001)
and that survival was higher in group 1 than in the other
groups, at both 6 and 24 h (p < 0.001) (Fig. 3a). The
overall 24-h difference was sustained for 30 days (p <
0.001) (Fig. 3b). These results suggest that in severe
trauma patients the survival rate depends on a high
PLT/RBC ratio rather than a high FFP/RBC ratio. Add-
itionally, Holcomb et al. [39] retrospectively investigated
the relationship between the PLT/RBC ratio and out-
come based on 643 trauma patients who received
massive transfusion. The patients were divided into three
groups: a low-ratio group (>1:20), a medium-ratio group
(1:2), and a high-ratio group (1:1). A propensity-adjusted
Kaplan–Meier survival plot showed that higher PLT
ratios were associated with improved survival at 24 h
and 30 days (p < 0.001 for both) (Fig. 4).
Johansson et al. [2] performed a meta-analysis of
the potential effect on survival of hemostatic resusci-
tation based on the proactive administration of PLTs
rather than RBCs in trauma patients with massive
bleeding. Two studies addressed the effect of high vs.
low PLT transfusion rates in 641 massively bleeding
trauma patients, of whom 333 received high PLT/RBC
ratio [40, 41]. According to these two studies, patients
receiving PLT/RBC in a high ratio had a significantly
lower mortality (odds ratio 0.45, 95% confidence interval
0.37–0.55). This finding could not be attributed to the
heterogeneity between the studies (I2 = 0%). However,
because no randomized studies evaluating the effect of
different transfusion ratios were included in this report,
the evidence level of this meta-analysis was low.
Additionally, the absence of a relationship between
the PLT/RBC ratio and overall mortality has been
reported [42, 43].
Fig. 2 Mortality of massively transfused patients at 24 h stratified by
platelet ratio. Adjusted for hypotension on admission (90 vs.
90 mmHg), GCS on admission (8 vs. 8), FFP/RBC ratio (%) at 24 h,
and cryoprecipitate at 24 h. FFP fresh frozen plasma, GCS Glasgow
Coma Scale, RBC red blood cell
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After considering the above findings, the adminis-
tration of at least one pool of PLTs (four to six indi-
vidual donor units) for every five units of RBCs to
trauma patients requiring massive transfusion seems
reasonable [44].
Combined therapy with RBC, FFP, and PLT
Previous investigations of the FFP/RBC transfusion ratio
supported a ratio of 1:1 or higher [10, 45]. However, in
the management of ATC/TIC, the simultaneous admin-
istration of not only RBCs and FFP but also PLTs, in
appropriate ratios, is recommended, with limited use of
crystalloid or colloid solution.
The “optimal” ratio is the subject of ongoing de-
bate because it may be complicated by the volumes
of anticoagulant and RBC additive solution in modern
blood components. In the abovementioned study by
Kornblith et al. [23], the differences in the INR, PTT, and
PLT counts obtained with whole blood vs. reconstituted
blood composed of either 1:1:1 or 2:1:1 ratios of units of
RBC, FFP, and PLT were investigated (Fig. 1). The results
of the present study showed that the mean INR of 1:1:1
reconstituted blood was 1.31 and the mean PTT 42 s (1.4
times > normal), whereas the values for 2:1:1 reconstituted
blood were 1.55 and 46 s (1.53 times > normal), respect-
ively. Moreover, PLT counts were higher for 1:1:1 than for
2:1:1 blood components (129 × 109/L vs. 95 × 109/L,
respectively), and typically, only 70% of the transfused
PLTs circulated (Table 1). This simple physical conse-
quence of mixing blood products suggests that treatment
Fig. 3 Kaplan–Meier survival plot for the first a 24 h and b 30 days after admission. a Kaplan–Meier survival plot for the first 24 h after admission
for the four groups (high plasma (FFPH) or platelet (PltH) to RBC ratio 1:2, low plasma (FFPL) or platelet (PltL) to RBC ratio 1:2). b Kaplan–Meier
survival plot for the first 30 days after admission for the four groups (high plasma (FFPH) or platelet (PltH) to RBC ratio 1:2, low plasma (FFPL) or
platelet (PltL) to RBC ratio 1:2). FFP fresh frozen plasma, RBCs red blood cells
Fig. 4 Propensity-adjusted Kaplan–Meier survival plot for the first a 24 h and b 30 days after admission. a Propensity-adjusted Kaplan–Meier
survival plot for the first 24 h after admission for the three platelet ratio groups: low (1:20), medium (1:2), and high (1:1). b Propensity-adjusted
Kaplan–Meier survival plot for the first 30 days after admission for the three platelet ratio groups: low (1:20), medium (1:2), and high (1:1)
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with 1:1:1 blood components has the greater potential to
correct ATC/TIC [26].
The potential of FFP/PLT/RBC = 1:1:1
In the last decade, an alternative resuscitation strategy was
developed based on providing only the conventional blood
components FFP, PLT, and RBC in a 1:1:1 ratio to main-
tain the intravascular volume, oxygen-carrying capacity,
plasma coagulation factors, and functioning platelets. The
administration of crystalloid fluids was markedly limited,
and other colloid-containing fluids given for massive
bleeding were avoided. In severely injured patients, this
strategy appears to not only save lives but also to reduce
blood product consumption [26]. In light of this result,
many guidelines now recommend 1:1:1 ratios.
Nascimento et al. [46] reported a feasibility study
based on a small randomized controlled trial that in-
cluded trauma patients expected to require a massive
transfusion. A fixed FFP/PLT/RBC ratio of 1:1:1 was
compared with standard practice (laboratory result-
guided transfusion protocol). The trial was able to
achieve the 1:1:1 ratio in 57% (21 of 37) of the patients
in the fixed ratio group compared with 6% (2 of 32) of
those in the control group, thus demonstrating the feasi-
bility of the intervention. While the study was not pow-
ered to detect a difference in mortality, the all-cause 28-
day mortality by intention-to-treat analysis (relative risk
for fixed ratio, 2.27; 95% confidence interval, 0.98–9.63)
and by per-protocol analysis (relative risk for fixed ratio,
3.17; 95% confidence interval, 1.15–18.24) was consist-
ent with a safe outcome.
The recent Pragmatic Randomized Optimal Plasma
and Platelet Ratios (PROPPR) trial [47], a large, pro-
spective, randomized, interventional trial in which pa-
tients with severe bleeding trauma were the focus
compared the efficacy and safety of a 1:1:1 transfusion
ratio of FFP/PLT/RBC to a 1:1:2 ratio. There was no dif-
ference in 24-h or 30-day mortality between the two
groups. However, a 1:1:1 ratio did result in a significant
reduction in mortality from bleeding within the first
24 h (9.2 vs. 14.6%; p = 0.03), with no increase for the
1:1:2 ratio group in ARDS, venous thromboembolism, or
other transfusion-related complications. The absolute
benefit was a 4% reduction in mortality among random-
ized patients, and the relative benefit a 15% reduction in
total mortality, from 26 to 22% overall.
However, the prospective observational PROMMTT
trial [3] emphasized anew the problems arising from bias
in the blood product delivery time. Despite the fact that
all 10 participating centers tried to deliver the products in
a 1:1:1 ratio, the fraction that succeeded in achieving this
ratio for plasma was 30% at 1 h, 40% at 2 h, and 50% at
6 h. The achieved ratios were even worse for PLTs [17].
Conclusion
Preventable trauma death may be attributable to the ab-
sence of appropriate initial resuscitation for bleeding.
Therefore, any effective resuscitation strategy must be
designed to complement the appropriate and prompt
correction of anemia, coagulopathy, and abnormalities
in fibrinolysis. In DCR, transfusion must be carried out
during the early stage of patient management. It involves
the use of increased amounts of plasma and PLTs along
with the first units of RBCs, while simultaneously min-
imizing crystalloid administration (1000-2000 mL) in pa-
tients who are predicted to require massive transfusion.
At the present time DCR is recommended for rapid
hemorrhage control through early administration of a
mixture of FFP, PLTs, and RBCs in a balanced ratio of
1:1:1.
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